Beijing Sunho Pharmaceutical Co (BJSE:920017) Other Financing: ¥-63.4 Mil (TTM As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BJSE:920017 Beijing Sunho Pharmaceutical Co Ltd BJSE:920017
80 GF Score
Price ¥15.67
GF Value ¥15.19
Valuation Fairly Valued
! 2 Warning Signs
View Full Analysis

What is Beijing Sunho Pharmaceutical Co Other Financing?

Beijing Sunho Pharmaceutical Co BJSE:920017 80 Other Financing is ¥-63.4 Mil as of Jun. 2026. GuruFocus rates BJSE:920017 with a GF Score™ of 80/100 and a GF Value™ of ¥15.19 (Fairly Valued). The stock has 2 warning signs investors should review.

Beijing Sunho Pharmaceutical Co's Other Financing for the three months ended in Jun. 2026 was ¥-69.5 Mil.

Beijing Sunho Pharmaceutical Co's Other Financing for the trailing twelve months (TTM) ended in Jun. 2026 was ¥-63.4 Mil.

Beijing Sunho Pharmaceutical Co Other Financing Historical Data

* Premium members only.

The historical data trend for Beijing Sunho Pharmaceutical Co's Other Financing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Beijing Sunho Pharmaceutical Co Other Financing Chart

Beijing Sunho Pharmaceutical Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Financing
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.41 0.00 7.32 -13.21 6.14

Beijing Sunho Pharmaceutical Co Quarterly Data
Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Other Financing Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -19.35 32.92 -26.77 -0.06 -69.47
BJSE:920017
80GF Score
Beijing Sunho Pharmaceutical Co Ltd BJSE:920017
Other Financing is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Beijing Sunho Pharmaceutical Co Other Financing Calculation

Other Financing represents other cash flow from financing activity that not otherwise classified, which includes:
Proceeds From Stock Option Exercised
Other Financing Charges

Other Financing for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥-63.4 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Other Financing →
What does a Other Financing of ¥-63.4 Mil mean?
Beijing Sunho Pharmaceutical Co (BJSE:920017) has a Other Financing of ¥-63.4 Mil as of Jun. 2026. Other Financing represents other cash flow from financing activity that not otherwise classified. View historical data for Beijing Sunho Pharmaceutical Co and its competitors.
Is Beijing Sunho Pharmaceutical Co's Other Financing too high?
Beijing Sunho Pharmaceutical Co's current Other Financing is ¥-63.4 Mil. Overall, Beijing Sunho Pharmaceutical Co has a GF Score™ of 80/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Beijing Sunho Pharmaceutical Co's Other Financing compare to ZTS?
Beijing Sunho Pharmaceutical Co's Other Financing of ¥-63.4 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Financing for a Drug Manufacturers company?
A good Other Financing depends on the Drug Manufacturers industry context. However, Other Financing should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Financing mean?
A high Other Financing can signal that a stock is expensive relative to its fundamentals. Other Financing represents other cash flow from financing activity that not otherwise classified. View historical data for Beijing Sunho Pharmaceutical Co and its competitors. Beijing Sunho Pharmaceutical Co's current Other Financing is ¥-63.4 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Beijing Sunho Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Beijing Sunho Pharmaceutical Co (BJSE:920017) is currently considered Fairly Valued. The stock's GF Value™ is ¥15.19, compared to a current price of ¥15.67 — trading 3.2% above its estimated fair value. The current Other Financing is ¥-63.4 Mil. Beijing Sunho Pharmaceutical Co's overall GF Score™ is 80/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Financing calculated?
Other Financing is calculated from a company's financial statements. For Beijing Sunho Pharmaceutical Co (BJSE:920017), the current Other Financing is ¥-63.4 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Beijing Sunho Pharmaceutical Co (BJSE:920017) Overvalued in 2026?

Based on GuruFocus' analysis, Beijing Sunho Pharmaceutical Co stock appears to be overvalued. The current stock price of ¥15.67 is trading 3.2% above its estimated GF Value™ of ¥15.19. GuruFocus considers Beijing Sunho Pharmaceutical Co to be Fairly Valued.

Key valuation signals for BJSE:920017:

  • Other Financing: ¥-63.4 Mil
  • GF Value™: ¥15.19 vs. price of ¥15.67 (3.2% above fair value)
  • GF Score™: 80/100 with 2 warning signs

No single metric tells the full story. See the BJSE:920017 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Beijing Sunho Pharmaceutical Co Business Description

Address No. 18, Zhonghe Street, Beijing Economic and Technological Development Zone, Beijing, CHN, 100176
Beijing Sunho Pharmaceutical Co Ltd engages in the research and development, production, and sales of pharmaceutical preparations while providing CMC/CMO integrated services for pharmaceutical preparation manufacturers and drug R&D enterprises. The company produces small-volume injections, freeze-dried powder injections, hard capsules, tablets, and other products. The company's main products included: compound digestive enzyme capsules, piracetam (small injection and powder injection), and oxalic acid acetate.
80GF Score

Get the complete analysis for BJSE:920017

Other Financing is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

¥15.67
Price
¥15.19
GF Value